RNA-sequencing analyses. (A) Increase or decrease of gene expression from screening to C3D22 by treatment arm. Genes include CD3D (T-cell gene), PDCD1 (PD-1), CD274 (PD-L1), IFN g sig (interferon-γ signature) (mean of CD274, LAG3, IFNG, CXCL9), CD34 (gene expressed on tumor cells), and PNMA5 (cancer testis antigen). The x-axis is the log₂ of the fold change between C3D22 and screening for patients with both time points. (B) Interferon-γ signature at screening and at C3D22 in responders (R) and nonresponders (NR) to treatment with azacitidine and durvalumab (Arm A) or azacitidine monotherapy (Arm B). The plot shows the fold change for those patients with screening samples and C3D22 samples. The y-axis is the log₂ of the fold change between C3D22 and screening. The horizontal line in the middle of each box is the mean, and the upper and lower borders of the boxes are the 90% CIs.